Investment ThemesDetailed Quotes
Weight Loss Drugs
Watchlist
GLP-1 weight-loss drug, whose full name is Glucagon-like peptide-1 receptor agonist. Initially, GLP-1 was a hormone secreted by the gastrointestinal tract mainly used for treating diabetes, but it has also been used to suppress appetite and control weight.
- 1509.788
- -37.687-2.44%
Close Mar 26 16:00 ET
1541.118High1509.427Low
1537.564Open1547.475Pre Close68.78MVolume--Rise37.87P/E (Static)4.81BTurnover--Flatline0.65%Turnover Ratio1.41TMarket Cap7Fall1.32TFloat Cap
Constituent Stocks: 7Top Rising: AMGN-0.37%
Sign in to post a comment
I guess whoever is behind this didn't get the results they wanted. PFE only drops by about 29 cents. ![]()
![]()
![]()
![]()
Shorting over 100M, you better have something more than this. You are going to get the mother of all squeeze (MOAS)!
$Pfizer (PFE.US)$ $SPDR S&P 500 ETF (SPY.US)$
Shorting over 100M, you better have something more than this. You are going to get the mother of all squeeze (MOAS)!
$Pfizer (PFE.US)$ $SPDR S&P 500 ETF (SPY.US)$
1
1
$Pfizer (PFE.US)$
Added some shares at 25.39 to DCA.
Added some shares at 25.39 to DCA.
1
$Pfizer (PFE.US)$
Pharma businesses are resilient to economic recession.
Pharma businesses are resilient to economic recession.
3
Oh boy… there’s some money behind this… but usually, big money avoids dividend stocks. This isn’t normal…
4
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Novo-Nordisk A/S (NVO.US)$ $1 dividend payout at the end of the month, with the new 52 week low, perhaps a good time to scoop some shares to hold for the long term. DCA recommended
5
1
$Viking Therapeutics (VKTX.US)$
Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
Viking Therapeutics (NASDAQ: VKTX) has completed enrollment in its Phase 2 VENTURE-Oral Dosing Trial of VK2735, a dual GLP-1 and GIP receptor agonist tablet for obesity treatment. The 13-week study enrolled 280 adults with BMI ≥30 kg/m2 or BMI ≥27 kg/m2 with weight-related conditions.
The trial's primary endpoint foc...
Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
Viking Therapeutics (NASDAQ: VKTX) has completed enrollment in its Phase 2 VENTURE-Oral Dosing Trial of VK2735, a dual GLP-1 and GIP receptor agonist tablet for obesity treatment. The 13-week study enrolled 280 adults with BMI ≥30 kg/m2 or BMI ≥27 kg/m2 with weight-related conditions.
The trial's primary endpoint foc...
1
1
$Viking Therapeutics (VKTX.US)$
Major Milestone: Viking's Oral Weight Loss Drug Advances with 280-Patient Phase 2 Trial
Major Milestone: Viking's Oral Weight Loss Drug Advances with 280-Patient Phase 2 Trial
1
1
$Novo-Nordisk A/S (NVO.US)$ even thou can see quite a volume of buy in. clearly it's trying to bottom out but still a falling knife
if further retests able to hold that final line around 73.3 there is still hope for some bounces. but as we can see from overall chart.. lower highs and low. not the best time to get in maybe start accumulating .
but this ticker definitely reminds me of amd..
both fell below 200ma . started to curve (more buying interest). and eventually a technical rebound. but l...
if further retests able to hold that final line around 73.3 there is still hope for some bounces. but as we can see from overall chart.. lower highs and low. not the best time to get in maybe start accumulating .
but this ticker definitely reminds me of amd..
both fell below 200ma . started to curve (more buying interest). and eventually a technical rebound. but l...
9
3
$Eli Lilly and Co (LLY.US)$
Lilly Unveils Groundbreaking Cancer Drug Pipeline: Dual Phase 1 Programs Target KRAS and SMARCA4 Mutations
Lilly Unveils Groundbreaking Cancer Drug Pipeline: Dual Phase 1 Programs Target KRAS and SMARCA4 Mutations
No comment yet
Demon Town : MOAS![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")